Cargando…
Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis
Etrolizumab is an IgG1‐humanized monoclonal antibody that specifically targets the β7 subunit of α4β7 and α4Eβ7 integrins, and it has been evaluated for the treatment of moderately‐to‐severely active ulcerative colitis (UC). Population pharmacokinetic (PK) analysis was performed to characterize etro...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469700/ https://www.ncbi.nlm.nih.gov/pubmed/35851998 http://dx.doi.org/10.1002/psp4.12846 |
_version_ | 1784788698846461952 |
---|---|
author | Moein, Anita Lu, Tong Jönsson, Siv Ribbing, Jakob Kassir, Nastya Zhang, Wenhui Sperinde, Gizette Zhang, Rong Tang, Meina Oh, Young S. Bruno, Rene Zhu, Rui |
author_facet | Moein, Anita Lu, Tong Jönsson, Siv Ribbing, Jakob Kassir, Nastya Zhang, Wenhui Sperinde, Gizette Zhang, Rong Tang, Meina Oh, Young S. Bruno, Rene Zhu, Rui |
author_sort | Moein, Anita |
collection | PubMed |
description | Etrolizumab is an IgG1‐humanized monoclonal antibody that specifically targets the β7 subunit of α4β7 and α4Eβ7 integrins, and it has been evaluated for the treatment of moderately‐to‐severely active ulcerative colitis (UC). Population pharmacokinetic (PK) analysis was performed to characterize etrolizumab PK properties in patients with moderately‐to‐severely active UC and evaluate covariate impacts on exposure. The population PK model was developed based on etrolizumab serum concentrations from patients with moderately‐to‐severely active UC enrolled in six studies (one phase I, one phase II, and four phase III) and validated using another phase III clinical trial. Stepwise covariate modeling was used to evaluate the impact of 23 prespecified covariates. Etrolizumab PK was best described by a two‐compartment model with first‐order absorption, with clearance decreasing over time. Population typical values were 0.260 L/day for clearance (CL) during the first dosing internal, 2.61 L for central volume, 71.2% for bioavailability, and 0.193/day for absorption rate. CL reduced over the study duration, the typical maximum reduction was 26% with an onset half‐life of 4.8 weeks. Consequently, the predicted mean terminal half‐life was shorter after a single dose (13.0 days) compared to that at steady‐state (17.1 days). Baseline body weight and albumin were the most impactful covariates for etrolizumab exposure. Final population PK model well characterized the PK properties of etrolizumab in patients with moderately‐to‐severely active UC and identified influential covariate effects. |
format | Online Article Text |
id | pubmed-9469700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94697002022-09-27 Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis Moein, Anita Lu, Tong Jönsson, Siv Ribbing, Jakob Kassir, Nastya Zhang, Wenhui Sperinde, Gizette Zhang, Rong Tang, Meina Oh, Young S. Bruno, Rene Zhu, Rui CPT Pharmacometrics Syst Pharmacol Research Etrolizumab is an IgG1‐humanized monoclonal antibody that specifically targets the β7 subunit of α4β7 and α4Eβ7 integrins, and it has been evaluated for the treatment of moderately‐to‐severely active ulcerative colitis (UC). Population pharmacokinetic (PK) analysis was performed to characterize etrolizumab PK properties in patients with moderately‐to‐severely active UC and evaluate covariate impacts on exposure. The population PK model was developed based on etrolizumab serum concentrations from patients with moderately‐to‐severely active UC enrolled in six studies (one phase I, one phase II, and four phase III) and validated using another phase III clinical trial. Stepwise covariate modeling was used to evaluate the impact of 23 prespecified covariates. Etrolizumab PK was best described by a two‐compartment model with first‐order absorption, with clearance decreasing over time. Population typical values were 0.260 L/day for clearance (CL) during the first dosing internal, 2.61 L for central volume, 71.2% for bioavailability, and 0.193/day for absorption rate. CL reduced over the study duration, the typical maximum reduction was 26% with an onset half‐life of 4.8 weeks. Consequently, the predicted mean terminal half‐life was shorter after a single dose (13.0 days) compared to that at steady‐state (17.1 days). Baseline body weight and albumin were the most impactful covariates for etrolizumab exposure. Final population PK model well characterized the PK properties of etrolizumab in patients with moderately‐to‐severely active UC and identified influential covariate effects. John Wiley and Sons Inc. 2022-07-29 2022-09 /pmc/articles/PMC9469700/ /pubmed/35851998 http://dx.doi.org/10.1002/psp4.12846 Text en © 2022 Genentech/Roch. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Moein, Anita Lu, Tong Jönsson, Siv Ribbing, Jakob Kassir, Nastya Zhang, Wenhui Sperinde, Gizette Zhang, Rong Tang, Meina Oh, Young S. Bruno, Rene Zhu, Rui Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis |
title | Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis |
title_full | Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis |
title_fullStr | Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis |
title_full_unstemmed | Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis |
title_short | Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis |
title_sort | population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469700/ https://www.ncbi.nlm.nih.gov/pubmed/35851998 http://dx.doi.org/10.1002/psp4.12846 |
work_keys_str_mv | AT moeinanita populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT lutong populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT jonssonsiv populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT ribbingjakob populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT kassirnastya populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT zhangwenhui populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT sperindegizette populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT zhangrong populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT tangmeina populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT ohyoungs populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT brunorene populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis AT zhurui populationpharmacokineticanalysisofetrolizumabinpatientswithmoderatelytoseverelyactiveulcerativecolitis |